Regina Deja

Learn More
Mass spectrometric analysis of the blood proteome is an emerging method of clinical proteomics. The approach exploiting multi-protein/peptide sets (fingerprints) detected by mass spectrometry that reflect overall features of a specimen's proteome, termed proteome pattern analysis, have been already shown in several studies to have applicability in cancer(More)
INTRODUCTION Currently CA 125 is a marker of choice for monitoring ovarian cancer Nonetheless, scientists are still searching for new markers, which could provide additional information for the evaluation of treatment, especially in patients with normal CA 125 levels, despite the progression of the disease. According to the latest reports, OPN can be a(More)
OBJECTIVE an attempt to determine the value of the simultaneous quantization of osteopontin (OPN), insulin-growth factor II (IGF II), leptin, prolactin and CA 125 for early detection of ovarian cancer. MATERIALS AND METHODS Prospective study of 69 women including: 15 females with ovarian cancer; 33 females with benign ovarian neoplasm; 21 disease-free(More)
The aim of this work was to evaluate the degree of bone resorption and incidence of osteoporosis in female postmenopausal patients with differentiated thyroid cancer treated with suppressive doses of thyroxine. During the regular follow-up of women with differentiated thyroid cancer, densitometry of lumbar spine (L2-L4) and femoral head were performed.(More)
OBJECTIVE To determine the usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and early monitoring after treatment completion in women diagnosed with cervical squamous cell carcinoma. MATERIAL AND METHODS Serum of 140 patients with diagnosed cervical squamous cell carcinoma was investigated. The women with the advanced stage of(More)
Monitoring patients with differentiated thyroid carcinoma (DTC) by thyroglobulin (Tg) measurements requires selecting optimal methods used for detection of this marker. An increase the thyroglobulin concentration in serum is a predictor of tumor recurrence. All serum thyroglobulin assays can be falsified by presence of Tg autoantibodies, which are present(More)
30 Abstract – Despite of relatively high rate of complete tumor responses after radiotherapy (RT) alone or in combination with chemotherapy (ChRT), locoregional relapse is a major reason of failure for patients with head and neck squamous cell carcinoma (HNC). If treatment failure is diagnosed early, salvage therapy could be possible. Such(More)
The study involved 214 patients of both sexes, including those treated at the Institute of Oncology in Gliwice and children treated for diabetes mellitus at the Diabetic++ Out-Patient Clinic in Gliwice. Blood glucose was assayed with GLUKOZA EO kit manufactured by POCh and strip test Glucostix (visually and with reflectance meter Glucometer II Ames). In(More)
PURPOSE There is a lack of effective diagnostic tools for early assessment of radiotherapy (RT) outcome in patients with head and neck cancer (HNC). The timely diagnosis of treatment failure may facilitate use of salvage procedures to prevent disease progression. We assessed squamous cell carcinoma antigen and CYFRA 21-1 as early markers of radiotherapy(More)